Personnel Information

写真a

INOUE Jun


Job title

Associate Professor

Mail Address

jun.cgen@mri.tmd.ac.jp

Degree 【 display / non-display

  • Doctorate of Science, Tottori University

Campus Career 【 display / non-display

  • 1900.01
    -
    2016.02
    Tokyo Medical and Dental University, Medical Research Institute, Medical Genomics, Molecular Cytogenetics, Assistant Professor
  • 1900.01
    -
    Now
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Advanced Therapeutic Sciences, Molecular Cytogenetics, Assistant Professor
  • 2009.04
    -
    2019.03
    Tokyo Medical and Dental University, Medical Research Institute, Medical Genomics, Molecular Cytogenetics, Junior Associate Professor
  • 2019.04
    -
    Now
    Tokyo Medical and Dental University, Medical Research Institute, Medical Genomics, Molecular Cytogenetics, Associate Professor

Research Areas 【 display / non-display

  • Pathological biochemistry

 

Published Papers & Misc 【 display / non-display

  1. Takemoto A, Tanimoto K, Mori S, Inoue J, Fujiwara N, Noda T, Inazawa J. Integrative genome-wide analyses reveal the transcriptional aberrations in Japanese esophageal squamous cell carcinoma. Cancer science. 2021.10; 112 (10): 4377-4392. ( PubMed, DOI )

  2. Liu C, Gen Y, Tanimoto K, Muramatsu T, Inoue J, Inazawa J. Concurrent targeting of MAP3K3 and BRD4 by <i>miR-3140-3p</i> overcomes acquired resistance to BET inhibitors in neuroblastoma cells. Molecular therapy. Nucleic acids. 2021.09; 25 83-92. ( PubMed, DOI )

  3. Inoue J, Inazawa J. Cancer-associated miRNAs and their therapeutic potential. Journal of human genetics. 2021.09; 66 (9): 937-945. ( PubMed, DOI )

  4. Gen Y, Muramatsu T, Inoue J, Inazawa J. miR-766-5p targets super-enhancers by downregulating CBP and BRD4. Cancer research. 2021.08; ( PubMed, DOI )

  5. Kishikawa M, Inoue J, Hamamoto H, Kobayashi K, Asakage T, Inazawa J. Augmentation of lenvatinib efficacy by topical treatment of <i>miR-634</i> ointment in anaplastic thyroid cancer. Biochemistry and biophysics reports. 2021.07; 26 101009. ( PubMed, DOI )

  6. Inoue J, Kishikawa M, Tsuda H, Nakajima Y, Asakage T, Inazawa J. Identification of PDHX as a metabolic target for esophageal squamous cell carcinoma. Cancer science. 2021.07; 112 (7): 2792-2802. ( PubMed, DOI )

  7. Inoue J, Fujiwara K, Hamamoto H, Kobayashi K, Inazawa J. Improving the Efficacy of EGFR Inhibitors by Topical Treatment of Cutaneous Squamous Cell Carcinoma with <i>miR-634</i> Ointment. Molecular therapy oncolytics. 2020.12; 19 294-307. ( PubMed, DOI )

  8. Takagawa Y, Gen Y, Muramatsu T, Tanimoto K, Inoue J, Harada H, Inazawa J. miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway. Molecular therapy : the journal of the American Society of Gene Therapy. 2020.06; 28 (6): 1494-1505. ( PubMed, DOI )

  9. Gokita K, Inoue J, Ishihara H, Kojima K, Inazawa J. Therapeutic Potential of LNP-Mediated Delivery of miR-634 for Cancer Therapy. Molecular therapy. Nucleic acids. 2020.03; 19 330-338. ( PubMed, DOI )

  10. Furusawa A, Miyamoto M, Takano M, Tsuda H, Song YS, Aoki D, Miyasaka N, Inazawa J, Inoue J. Ovarian cancer therapeutic potential of glutamine depletion based on GS expression. Carcinogenesis. 2018.05; 39 (6): 758-766. ( PubMed, DOI )

  11. Tonouchi E, Gen Y, Muramatsu T, Hiramoto H, Tanimoto K, Inoue J, Inazawa J. Publisher Correction: miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein. Scientific reports. 2018.04; 8 (1): 6769. ( PubMed, DOI )

  12. Tonouchi E, Gen Y, Muramatsu T, Hiramoto H, Tanimoto K, Inoue J, Inazawa J. miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein. Scientific reports. 2018.03; 8 (1): 4482. ( PubMed, DOI )

  13. Akdemir B, Nakajima Y, Inazawa J, Inoue J. <i>miR-432</i> Induces NRF2 Stabilization by Directly Targeting KEAP1. Molecular cancer research : MCR. 2017.11; 15 (11): 1570-1578. ( PubMed, DOI )

  14. Takahashi H, Inoue J, Sakaguchi K, Takagi M, Mizutani S, Inazawa J. Autophagy is required for cell survival under L-asparaginase-induced metabolic stress in acute lymphoblastic leukemia cells. Oncogene. 2017.07; 36 (30): 4267-4276. ( PubMed, DOI )

  15. Okuda M, Inoue J, Fujiwara N, Kawano T, Inazawa J. Subcloning and characterization of highly metastatic cells derived from human esophageal squamous cell carcinoma KYSE150 cells by in vivo selection. Oncotarget. 2017.05; 8 (21): 34670-34677. ( PubMed, DOI )

  16. Xu H, Miki K, Ishibashi S, Inoue J, Sun L, Endo S, Sekiya I, Muneta T, Inazawa J, Dezawa M, Mizusawa H. Transplantation of neuronal cells induced from human mesenchymal stem cells improves neurological functions after stroke without cell fusion. J Neurosci Res. 2010.12; 88 (16): 3598-3609. ( PubMed, DOI )

  17. Inoue J, Misawa A, Tanaka Y, Ichinose S, Sugino Y, Hosoi H, Sugimoto T, Imoto I, Inazawa J. Lysosomal-associated protein multispanning transmembrane 5 gene (LAPTM5) is associated with spontaneous regression of neuroblastomas. PLoS One. 2009; 4 (9): e7099. ( PubMed, DOI )

  18. Zhao C, Inoue J, Imoto I, Otsuki T, Iida S, Ueda R, Inazawa J. POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17. Oncogene. 2008.01; 27 (1): 63-75. ( PubMed, DOI )

  19. Sugino Y, Misawa A, Inoue J, Kitagawa M, Hosoi H, Sugimoto T, Imoto I, Inazawa J. Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas. Oncogene. 2007.11; 26 (53): 7401-7413. ( PubMed, DOI )

  20. Tanaka K, Imoto I, Inoue J, Kozaki K, Tsuda H, Shimada Y, Aiko S, Yoshizumi Y, Iwai T, Kawano T, Inazawa J. Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma. Oncogene. 2007.09; 26 (44): 6456-6468. ( PubMed, DOI )

  21. Yu W, Imoto I, Inoue J, Onda M, Emi M, Inazawa J. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene. 2007.02; 26 (8): 1178-1187. ( PubMed, DOI )

  22. Misawa A, Inoue J, Sugino Y, Hosoi H, Sugimoto T, Hosoda F, Ohki M, Imoto I, Inazawa J. Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification. Cancer Res. 2005.11; 65 (22): 10233-10242. ( PubMed, DOI )

  23. Izumi H, Inoue J, Yokoi S, Hosoda H, Shibata T, Sunamori M, Hirohashi S, Inazawa J, Imoto I. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum Mol Genet. 2005.04; 14 (8): 997-1007. ( PubMed, DOI )

  24. Tanami H, Imoto I, Hirasawa A, Yuki Y, Sonoda I, Inoue J, Yasui K, Misawa-Furihata A, Kawakami Y, Inazawa J. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene. 2004.11; 23 (54): 8796-8804. ( PubMed, DOI )

  25. Inazawa J, Inoue J, Imoto I. Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci. 2004.07; 95 (7): 559-563. ( PubMed )

  26. Inoue J, Otsuki T, Hirasawa A, Imoto I, Matsuo Y, Shimizu S, Taniwaki M, Inazawa J. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol. 2004.07; 165 (1): 71-81. ( PubMed, DOI )

  27. Sonoda I, Imoto I, Inoue J, Shibata T, Shimada Y, Chin K, Imamura M, Amagasa T, Gray JW, Hirohashi S, Inazawa J. Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer Res. 2004.06; 64 (11): 3741-3747. ( PubMed, DOI )

  28. Hirasawa A, Aoki D, Inoue J, Imoto I, Susumu N, Sugano K, Nozawa S, Inazawa J. Unfavorable prognostic factors associated with high frequency of microsatellite instability and comparative genomic hybridization analysis in endometrial cancer. Clin Cancer Res. 2003.11; 9 (15): 5675-5682. ( PubMed )

  29. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, Nozawa S, Inazawa J, Imoto I. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res. 2003.06; 9 (6): 1995-2004. ( PubMed )

  30. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, Inazawa J. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 2003.04; 63 (8): 1876-1883. ( PubMed )

  31. Yu W, Inoue J, Imoto I, Matsuo Y, Karpas A, Inazawa J. GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines. J Hum Genet. 2003; 48 (6): 331-335. ( PubMed, DOI )

  32. Janssen JW, Imoto I, Inoue J, Shimada Y, Ueda M, Imamura M, Bartram CR, Inazawa J. MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas. J Hum Genet. 2002; 47 (9): 460-464. ( PubMed, DOI )

▼display all

Patents 【 display / non-display

  • METHOD FOR ASSAYING MICRORNA, CANCER THERAPEUTIC AGENT, AND MEDICINAL COMPOSITION CONTAINING SAME FOR CANCER THERAPY

    Patent Number: 9994843

Awards & Honors 【 display / non-display

  • Scholar-in-Training Award, American Association for Cancer Research (AACR),2005

Others 【 display / non-display

  • Anti-cancer dream cream shrinks oral tumors,2022.03

    AAAS EurekAlert! The Global Source for Science News